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The 1,5-diarylpyrrole derivative BM212 was previously shown to be active against multidrug-resistant clinical isolates andMyco-
bacterium tuberculosis residing within macrophages as well as againstMycobacterium avium and other atypical mycobacteria.
To determine its mechanism of action, we identified the cellular target. SpontaneousMycobacterium smegmatis,Mycobacterium
bovis BCG, andM. tuberculosisH37Rv mutants that were resistant to BM212 were isolated. By the screening of genomic libraries
and by whole-genome sequencing, we found that all the characterized mutants showedmutations in themmpL3 gene, allowing
us to conclude that resistance to BM212maps to theMmpL3 protein, a member of the MmpL (mycobacterialmembrane protein,
large) family. Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonylcyanidem-chlorophenylhydrazone,
and verapamil. Uptake/efflux experiments with [14C]BM212 demonstrated that resistance is not driven by the efflux of BM212.
Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212.
The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis, the causative
agent of tuberculosis (TB),makes the validation of new antituber-
cular agents a major global priority. Since tubercular drug resis-
tance is chromosomally encoded (17), chemotherapeutic agents
directed against new cellular targets are likely to be effective
against both drug-sensitive and drug-resistant M. tuberculosis
strains (5, 12, 13, 18). Target identification and validation are
usually achieved by either genetic or chemical approaches. The
former has the advantage of identifying a likely cellular target a
priori but yields no information with regard to the druggability of
the target and the access of the drug to the target (a particular
problem in mycobacteria [23]). It is therefore not surprising that
no current antitubercular agents have been identified through ra-
tional drug design (23). Alternatively, the identification of a cel-
lular target candidate through chemical screening has the advan-
tage of knowing that the compound can bind and affect the
cellular target in vivo. The identification of the target for an active
compound allows the rational modification of lead candidates
through medicinal chemistry while ensuring that the compound
retains activity against its primary target. However, finding which
proteins are inhibited by a compound can be quite challenging.
We randomly screened a library of compounds to identify
structures of interest for further development. Several azole com-
pounds containing imidazole, pyrrole, toluidine, ormethanamine
groups were tested for antimycobacterial activity. Among them,
1-{[1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]methyl}-
4-methylpiperazine (BM212) (Fig. 1) proved to be active against
multidrug-resistant clinical isolates, againstM. tuberculosis resid-
ingwithinmacrophages, and againstMycobacteriumavium aswell
as other nontuberculous mycobacteria (7). The identification of
BM212 as a hit within this compound class provided the stimulus
to develop novel structures that could be endowed with less toxic
features and better activities (3, 4).
Having identified a group of related compounds with potent
antimycobacterial activity, we proceeded to identify the cellular
target of BM212 as the prototype compound in its class. Here, by
complementary genetic approaches, we propose that the MmpL3
protein is the cellular target for BM212.
MATERIALS AND METHODS
Synthesis of BM212. All chemicals were used at a purity of 95%. A
Discovery Microwave System apparatus (from CEM Corporation) was
used for Stetter and Paal-Knorr reactions. Melting points were deter-
mined with open capillaries on a Gallenkamp apparatus and are uncor-
rected. Microanalyses were conducted with a Perkin-Elmer 240C or a
Perkin-Elmer series II CHNS/OAnalyzer 2400 instrument. Fluka silica gel
60 (230 to 400 mesh) was used for column chromatography. Fluka TLC
plates (silica gel 60 F254)were used for thin-layer chromatography (TLC).
Fluka aluminum oxide (activity II-III, according to the Brockmann scale)
was used for chromatographic purifications. Fluka Stratocrom aluminum
oxide plates with a fluorescent indicator were used for TLC to check the
purity of the compounds. High-performance liquid chromatography
(HPLC) analyseswere conductedwith aWaters Alliance 2695 instrument,
using a UV-visible light (Vis) Waters PDA 996 detector and working at
333 nm. All synthesized compounds were95% pure. 13C nuclear mag-
netic resonance (NMR) and 1HNMR spectra were recordedwith a Bruker
AC 400 spectrometer in CDCl3 (with tetramethylsilane [TMS] as the in-
ternal standard).
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BM212 was synthesized as previously reported (3, 4). Briefly, 1-(4-
chlorophenyl)pentane-1,4-dione was obtained by reacting the 4-Cl-
benzaldehyde with methyl vinyl ketone. The resulting 1,4-diketone was
cyclized in the presence of 4-Cl-aniline to yield 1,2-bis(4-chlorophenyl)-
5-methyl-1H-pyrrole. BM212 was finalized by reacting 1,5-diarylpyrrole
with formaldehyde and N-methylpiperazine under Mannich reaction
conditions.
DNA cloning and amplification.The shuttle cosmid pYUB18 (12 kb)
was used to construct genomic libraries (10). Primers YUB3 and YUB4
(Table 1), recognizing short sequences upstream and downstream of
the BamHI restriction site, were utilized for the partial sequencing of
genomic inserts. Subcloning experiments with one of the cosmids con-
ferring BM212 resistance were performed by cloning into the pGEM-T
Easy vector (Promega) and then into the final vectors pSUM39 (1) and
pMD31 (9).
For several strains of Mycobacterium bovis BCG and M. tuberculosis
H37Rv, results from whole-genome sequencing were confirmed by the
cloning of the mmpL3 gene into pBluescript, followed by the targeted
resequencing ofmmpL3.
All primers used for PCR amplification are listed in Table 1. Amplifi-
cation reactions were performed with a final volume of 40 l containing
200 M each deoxynucleotide triphosphate (dNTP), 500 nM each
primer, 2%dimethyl sulfoxide (DMSO), 2.5mMMgCl2, 40 ng of plasmid
DNA or 100 ng of genomic mycobacterial DNA, and 1 U of Pfu DNA
polymerase (Promega). Cycling conditions were as follows: denaturation
at 95°C for 2min, followed by 30 cycles of denaturation at 95°C for 1min,
annealing for 30 s at a temperature dependent on the primers used, and
elongation at 72°C for a time dependent on the product size, with a final
elongation step at 72°C for 5 min.
PCRproducts were blunted into pBluescript at the EcoRV site, and the
mmpL3 gene was sequenced by using primers listed in Table 1.
Bacterial strains, media, and growth conditions. Escherichia coli
HB101 was used as a host strain and for the construction of genomic
libraries; the E. coli XL1-Blue MRF= Tetr strain (Stratagene) was used for
cloning procedures. These strains were grown in Luria-Bertani (LB) broth
or on LB agar (20). Plates were supplemented, when required, with tetra-
cycline (12.5 g/ml) (Sigma), ampicillin (50 g/ml) (Sigma), kanamycin
(50 g/ml) (Sigma), and streptomycin (50 g/ml) (Duchefa Biochimie
B.V.). All strains were grown aerobically at 37°C with shaking (200 rpm).
The plates were incubated at 37°C for 1 day.
Mycobacterium smegmatiswild-type strainmc2155 andmutant strains
MSMEG-GR12.5 and MSMEG-BM1 to MSMEG-BM10 (Table 2) were
grown in Middlebrook 7H9 medium (Difco) supplemented with 10%
oleic acid-albumin-dextrose-catalase (OADC) enrichment broth (Difco)
and 0.05% Tween 80 or on 7H11 agar (Difco) supplemented with 10%
OADC and 0.5% glycerol. When required, kanamycin was added at a
concentration of 25 g/ml. All cultures were grown aerobically at 37°C
with shaking (200 rpm). The plates were incubated at 37°C for at least 3
days.
M. smegmatis wild-type strain mc2155 and mutant strains
SRBM212_20, SRBM212_21, SRBM212_24, and SRBM212_26 (Table 2)
were grown in Middlebrook 7H9 medium (Difco) supplemented with
10% albumin-dextrose-catalase (ADC), 0.05% Tween 80, and 0.2% glyc-
erol or on 7H10 agar (Difco) supplemented with 10% ADC and 0.5%
glycerol. All cultures were grown aerobically at 37°C with shaking (160
rpm). The plates were incubated at 37°C for at least 5 days.
Mycobacterium bovis wild-type strain BCG and mutants resistant to
BM212, BCG-BM40 to BCG-BM44, and BCG-BM49 to BCG-BM56 (Ta-
ble 3), were grown as described above forM. smegmatis at 37°C for about
FIG 1 Chemical structure of BM212. Me, methyl.
TABLE 1 Oligonucleotides used in this work
Oligonucleotide Sequence Purpose
BM1 GTGGGCGGCATCCTGACCTTCGT Sequencing of theM. smegmatis 5.2-kb ScaI/EcoRV fragment
BM2 AACGCGCCCAGCCAGGACTCG containing themmpL3 gene
BM3 GCCGTCGACATACCGCGTTCA
BM4 GAATTGCTCCTGCGACTGGCG
BM5 AAGTGCACGGGGGTGAACTCGG
BM6 CCAGGCGAACACTTAGGCTC
BM7 TTTCCTCCGCGCCGACACCGT
YUB3 GCAGATCCGGCCCAGATTTC pYUB18 cosmid sequencing
YUB4 TGGCGGCGGCACGTTCATCA
MMPLB1 GACGTGTGTGACAACCAAA Sequencing of theM. bovis BCGmmpL3 gene
MMPLB3 AACGGCGAATGGAAGTGCT
MMPLB5 ATCCTGTCTATCACCGTGTTG
MMPLB7 ACCCCGCCCAAAGGAATCAC
MMPLB9 TCGGTGATGAAGCTGCTCGG
Rv0206_seq1 GACGTGGTGGACAACCAAAAAG Subcloning and sequencing of theM. tuberculosis
Rv0206_seq2 GAATGGAAGTGCTGGCGC mmpL3 gene
Rv0206_seq3 TCAGCGAGAAGTACTTGCC
Rv0206_seq4 CATCATTACCGCCGCGGCG
Rv0206_seq5 AATCATACGGTCGGACGGC
Rv0206_PCRf AGGACATCGCTGGTGTTTTCCGG
Rv0206_PCRr GCTTTCTTCAACAATGCGGTGCA
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3 to 4 weeks under static conditions, while plates were incubated at 37°C
for at least 3 weeks.
Wild-typeM. bovis BCG andM. bovismutant strains BCGRBM212_1
and BCGRBM212_2 (Table 3) were also grown in Middlebrook 7H9 me-
dium (Difco) supplemented with 10% ADC, 0.05% Tween 80, and 0.2%
glycerol or on 7H10 agar (Difco) supplemented with 10% ADC and 0.5%
glycerol at 37°C for about 10 days with shaking (160 rpm). The plates were
incubated at 37°C for at least 4 weeks.
M. tuberculosis wild-type strain H37Rv and mutant strain
TBRBM212_1 (Table 3) were grown in Middlebrook 7H9 medium
(Difco) supplemented with 10%OADC, 0.05%Tween 80, and 0.2% glyc-
erol or on 7H10 agar (Difco) supplemented with 10% OADC and 0.5%
glycerol at 37°C for approximately 3 weeks with shaking (160 rpm). The
plates were incubated at 37°C for at least 8 weeks.
Drug susceptibility tests. MICs of compounds (BM212, isoniazid
[INH], and pump inhibitors) for M. smegmatis, M. bovis BCG, and M.
tuberculosis H37Rv strains were determined with both solid and liquid
media.
For assays performed with solid media, 7H11 agar medium supple-
mented with 10% OADC and 0.5% glycerol was used to prepare plates
containing 2-fold serial dilutions of BM212 dissolved in DMSO at a con-
centration ranging from0.17 to 100g/ml. Cell cultures were grown to an
optical density at 600 nm (OD600) of 0.8 and diluted to a final concentra-
tion of 2  106 CFU/ml. One microliter of the diluted culture was then
streaked onto each plate and incubated at 37°C for 3 to 4 days, 4 to 5weeks,
or 8 weeks for M. smegmatis, M. bovis BCG, or M. tuberculosis H37Rv,
respectively. The MIC was defined as the lowest concentration of drug
that prevented the formation of colonies.
For assays performed with liquid media, the MIC was defined as the
lowest concentration of drug that yielded an absence of visual turbidity.
BM212 and INH, prepared in ethanol and sterile water, respectively, were
dissolved in 3 ml of Middlebrook 7H9 medium, to a final concentration
ranging from 0.125 to 100 g/ml, in 2-fold serial dilutions. The medium
was then inoculated with mycobacteria to an OD600 of 0.003 ofM. smeg-
matis,M. bovis BCG, orM. tuberculosisH37Rv and incubated at 37°C for
24 h, 10 days, or 12 days, respectively. A control tube or inkwell without
any drug was included with each experiment, and INH was used as a
control.
Isolation of M. smegmatis, M. bovis BCG, and M. tuberculosis mu-
tants resistant to BM212.M. smegmatismutant strains MSMEG-GR12.5
and MSMEMG-BM1 to MSMEG-BM10 (Table 2), resistant to BM212,
were isolated by plating about 1010 cells on 7H11 solid medium contain-
ing a gradient of the compound (21) as well as with different concentra-
tions of BM212, ranging from 3.125 to 100g/ml.M. bovismutant strains
BCG-BM40 to BCG-BM44 and BCG-BM49 to BCG-BM56 (Table 3),
resistant to BM212, were also isolated by plating about 1010 cells onto
7H11 solid mediumwith concentrations of BM212 ranging from 3.125 to
100 g/ml.
M. smegmatis SRBM212_20, SRBM212_21, SRBM212_24, and
SRBM212_26 (Table 2); M. bovis BCGRBM212_1 and BCGRBM212_2;
and M. tuberculosis TBRBM212_1 (Table 3), resistant to BM212, were
isolated as follows. ForM. smegmatismc2155, 5 108 CFU/ml was plated
onto 7H10medium containing different concentrations of BM212, rang-
ing from 0.1 to 30 g/ml. ForM. bovis BCG, 5 108 CFU/ml was plated
onto 7H10 agar containing concentrations of BM212 ranging from3 to 10
g/ml. ForM. tuberculosisH37Rv, 5 108 CFU/ml was plated onto 7H10
agar containing concentrations of BM212 ranging from 2 to 10 g/ml.
TABLE 2MICs of BM212 and amino acid substitutions in the mmpL3 gene ofM. smegmatismutants resistant to BM212a
M. smegmatis strain(s) MIC (g/ml)
Amino acid change
(position) Mutation(s) in anotherM. smegmatis ORF(s)
mc2155 (wt) 3.125
MSMEG-GR12.5 12.5 A254V
I296L
MSMEG-BM1, MSMEG-BM2, MSMEG-BM7,
MSMEG-BM8
12.5 I249T
MSMEG-BM3, MSMEG-BM4 12.5 F240L
MSMEG-BM6 12.5 L196P
MSMEG-BM9 12.5 A347V
MSMEG-BM10 12.5 V689G
SRBM212_20 25 A326T
SRBM212_21 25 A326T MSMEG_2883, T130T
SRBM212_24 25 V689G MSMEG_0931c,C; 3682514, TC (noncoding); deletion of
MSMEG_1716–MSMEG_1726
SRBM212_26 25 V197M
a The different nomenclatures of strains refer to mutants isolated during different experiments (see Materials and Methods). wt, wild type.
TABLE 3MICs of BM212 and amino acid substitutions in the mmpL3
genes ofM. bovis BCG andM. tuberculosisH37Rv mutants resistant to
BM212a
Strain(s)
MIC
(g/ml)
Amino acid
change (position)
M. bovis
BCG (wt) 0.78
BCG-BM40 6.25 I250M
L320P
BCG-BM41 6.25 T286K
L320P
BCG-BM42, BCG-BM43, BCG-BM49,
BCG-BM52–BCG-BM56
3.12 L320P
BCG-BM44 3.12 T277M
L320P
BCG-BM50 3.12 A316T
L320P
BCG-BM51 3.12 A294T
L320P
BCGRBM212_1 20 L320P
BCGRBM212_2 20 V240A
M. tuberculosis
H37Rv (wt) 1.5
TBRBM212_1 25 L215S
a The different nomenclatures of strains refer to mutants isolated during different
experiments (see Materials and Methods).
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Control 7H10 plates containing 30 g/ml of INH inoculated with either
5  108 CFU/ml of M. smegmatis mc2155, 5  108 CFU/ml of M. bovis
BCG, or 5 108 CFU/ml ofM. tuberculosisH37Rv were used. The plates
were incubated at 37°C for 7 days in the case ofM. smegmatis, 4 weeks for
M. bovis BCG, and 8 weeks forM. tuberculosisH37Rv.
MIC determinations in the presence of efflux inhibitors. The MICs
of the efflux pump inhibitors reserpine (RES) (a plant alkaloid known to
inhibit the transport of drugs extruded by ATP-energized pumps), car-
bonylcyanide m-chlorophenylhydrazone (CCCP) (a proton uncoupler),
and verapamil (VER) (a calcium channel blocker) were determined forM.
smegmatis mc2155. The susceptibilities of M. smegmatis strains mc2155,
MSMEG-GR12.5, and SRBM212_20 to BM212 were then tested in the
presence of subinhibitory concentrations of CCCP (7.5 g/ml), RES (12
g/ml), and VER (40 g/ml). The MICs of the pump inhibitors alone or
in the presence of BM212 were determined in liquidmedium, as reported
above.
Whole-genome sequencing. Resistant mutants selected for whole-
genome sequencing were sequenced with an Illumina GenomeAnalyzer II
instrument in the paired-endmode with 51-bp reads. Genomic DNAwas
extracted from log-phase cultures by using a MasterPure purification kit
(Illumina) according to the manufacturer’s instructions. A total of 2 to 3
g of DNA for each sample was sheared by using a Covaris sonicator, and
the standard Illumina sample preparation procedure was followed, in-
cluding blunt-end repair, adapter ligation, PCR amplification, and size
selection of 350- to 450-bp fragments on a 2% agarose gel, as described by
the manufacturer (Multiplexing SamplePrep guide 1005361_D; Illu-
mina). Samples were loaded onto a flow cell, clusters were generated by
using a ClusterStation instrument, sequencing by synthesis was carried
out using TruSeq kit v.5, and images were collected and analyzed by using
Illumina Offline Basecaller v1.8. Each data set, consisting of10 million
pairs of 51-bp reads, was aligned to the genome sequence of the parental
strain (allowing up to 2 mismatches per read with no gaps, requiring
paired reads to map within 500 bp of each other), and polymorphisms
(single-nucleotide polymorphisms [SNPs] and indels) were identified by
using software developed at Texas A&M University.
[14C]BM212 accumulation. The accumulation of BM212 was evalu-
ated with wild-type M. smegmatis mc2155 and mutant strain MSMEG-
GR12.5. Mycobacterial cells were grown to anOD600 of 0.5 to 0.8 in 90ml
of 7H9 medium supplemented with Tween 80 and 0.2% glycerol. Cells
were then washed twice at 5,000 rpm for 20 min with 10 ml 0.1 M phos-
phate buffer (pH 8.0) and resuspended in 4ml of the same buffer contain-
ing 1 mMMgSO4 and 0.2% glycerol. After incubation at 37°C for 15 min
at 200 rpm, the assay was started by addition of the radiolabeled
[14C]BM212 (0.25 mCi/ml) (Vitrax) at a final concentration of 1.9M to
the culture, and the culture was again incubated at 37°C with gentle shak-
ing. At various time points, 50 l of the suspension (in duplicate) was
removed, diluted in 1ml of 0.1M chilled phosphate buffer containing 0.1
M LiCl, and filtered through 0.45-m-pore-size filters (Millipore). The
filters were washed twice with 5 ml of the same buffer, and the radioactiv-
ity retained on the filter was determined with a Perkin-Elmer Trilux Mi-
croBeta 1450 Counter by using an Ecolume scintillation cocktail (ICN
Biomedicals). The efflux experiment was repeated three times.
RESULTS
Isolation of M. smegmatis, M. bovis BCG, and M. tuberculosis
H37Rv mutant strains resistant to BM212. The MIC of BM212
against different mycobacterial species was evaluated as described
in Materials and Methods. BM212 showed good potency against
all mycobacterial species tested, as previously described (3, 4, 7)
(Tables 2 and 3).
We isolated and characterized mycobacterial strains resistant
to BM212 in order to identify the cellular target of BM212. The
plating ofM. smegmatis onto solid media containing various con-
centrations of BM212 yielded multiple isolates that exhibited
higher MICs of BM212 than the parent strain (Table 2). The MIC
of BM212 for wild-type M. smegmatis strain mc2155 was 3.12
g/ml (Table 2). Mutants arose at a frequency of 3.7  107.
Fourteen out of 61 resistant isolates were characterized and
showed MIC values ranging from 12.5 to 25 g/ml, 4- to 8-fold
higher than those for the parent strain (Table 2). Isolates of the
vaccine mycobacterial strain M. bovis BCG and M. tuberculosis
H37Rv that were resistant to BM212 were selected by using a sim-
ilar strategy. TheMICs of BM212 for wild-typeM. bovis BCG and
M. tuberculosisH37Rv were 0.78 and 1.5 g/ml, respectively (Ta-
ble 3). Fifteen out of 18 resistant isolates of M. bovis BCG were
characterized and showed MIC values ranging from 3.12 to 20
g/ml, 4- to 25-fold higher than those for the parent strain (Table
3). TheMIC of BM212 for the only resistantM. tuberculosis strain
was 20 g/ml, 10-fold the MIC for the parent strain (Table 3).
Mutants were isolated at frequencies of 1.7  108 for M. bovis
and 2 109 forM. tuberculosis.
Screening of cosmid libraries derived fromBM212-resistant
M. smegmatis isolates identified mutations in themmpL3 gene
as mediating resistance to BM212. Genomic DNAs from two
BM212-resistant isolates of M. smegmatis, MSMEG-GR12.5 and
MSMEG-BM10, were used to construct two cosmid libraries by
using vector pYUB18 (10) and were transformed into E. coli cells.
The isolated cosmid DNA was transformed into wild-type M.
smegmatismc2155 cells by electroporation, and the transformants
were plated onto selective medium containing BM212 at concen-
trations ranging from 3.12 g/ml to 50 g/ml. Resistant colonies
were first validated to ensure that they were truly resistant to
BM212. The MIC of BM212 for isolated colonies was 12.5 g/ml,
i.e., 4-fold the MIC for the same strain transformed with vector
pYUB18. Cosmid DNA was extracted from the resistant clones
and retransformed intoM. smegmatismc2155 to confirm that re-
sistance was due to the cosmid and not to the generation of spon-
taneous resistance. As expected, all the cosmids conferred resis-
tance to BM212.
The cosmids responsible for the resistance phenotype were
partially sequenced, and sequences were compared with those of
M. smegmatis mc2155 by using BlastN (http://blast.ncbi.nlm.nih
.gov/Blast.cgi). All cosmids that mediated resistance contained a
partially overlapping fragment. The cosmid derived from the
screening of the genomic library from the resistant isolate
MSMEG-GR12.5 contained a 22-kb genomic DNA insert with 2
partial genes and 16 intact genes. This fragment was digested with
restriction enzymes and further subcloned into vectors pMD31
and pSUM39. Transformants containing these plasmids were
again screened for resistance to BM212. A 5.2-kb ScaI/EcoRV
fragment was found to confer resistance to BM212 and contained
three genes,MSMEG_0249 (1,140 bp),MSMEG_0250 (3,042 bp),
and MSMEG_0251 (699 bp), which code for an integral mem-
brane protein, the MmpL3 protein, and a hypothetical protein,
respectively. The cloned DNA was sequenced, and the sequence
was comparedwith the referenceM. smegmatis genome.While the
sequences forMSMEG_0249 andMSMEG_0251were identical to
thewild-type sequence, themmpL3 sequence contained 2 nonsyn-
onymousmutations comparedwith the reference sequence. These
encoded amino acid substitutions from alanine to valine at posi-
tion 254 (A254V) and from isoleucine to leucine at position 296
(I296L) (Table 2).
For the cosmid derived from the screening of the genomic
library from the resistant isolate MSMEG-BM10, a single muta-
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tion rendering an amino acid substitution fromvaline to glycine at
position 689 (V689G) in themmpL3 gene was found (Table 2).
Given the results achieved with the screening of cosmid librar-
ies, the mmpL3 genes from the other nine resistant M. smegmatis
mutants (MSMEG-BM1 to MSMEG-BM9) were amplified and
sequenced. The analysis of these sequences revealed pointmutations
which caused an amino acid change for eachmutant tested (Table 2).
Altogether, these results suggest that mutations in themmpL3 gene
are responsible for BM212 resistance. As shown in Fig. 2A, the
majority of these amino acid changes map within the first six
transmembrane segments of the predicted MmpL3 topology.
Whole-genome sequencing of resistant isolates to identify
mutations responsible for BM212 resistance. Among isogenic
mutants resistant to BM212, the isolates with the highest MICs,
SRBM212_20, SRBM212_21, SRBM212_24, and SRBM212_26
(Table 2), were selected for whole-genome sequencing to identify
FIG 2 Predicted topology of MmpL3 from M. smegmatis (MSMEG_0250) (A) and M. bovis BCG (BCG0243c) (B). The arrows indicate the amino acid
substitutions observed for M. smegmatis (A) (see also Table 2) and M. bovis (B) (see also Table 3) mutants resistant to BM212. The amino acid substitution
observed for the only resistantM. tuberculosismutant is highlighted in gray. The MEMSAT2 program was used to predict topology (11).
La Rosa et al.
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polymorphisms linked with resistance. We used an Illumina
GenomeAnalyzer instrument with 51-bp reads in the paired-end
mode, yielding a mean depth of coverage of 50 to 78 (number
of reads covering each nucleotide) and a completion of 99.9%
(fraction of sites covered by at least one read). Compared to the
genome sequence of the parental strain M. smegmatis mc2155,
each strain was observed to have a nonsynonymous substitution
in the mmpL3 gene (MSMEG_0250), including the mutations
A326T, V689G, and V197M (Table 2). As shown in Fig. 2A, the
first and the second of these amino acid changes map to trans-
membrane segments, while the last one lies within a cytoplasmic
domain of the predicted MmpL3 topology.
For two of the strains, these were the only polymorphisms de-
tected in the entire genome. The other two strains had additional
polymorphisms, although one was synonymous (MSMEG_2883,
T130T), one was in a noncoding region, and one was a frameshift
mutation in a hypothetical protein (MSMEG_0931c) (Table 2).
Strain SRBM212-24 also had an 8,566-bp deletion of
MSMEG_1716 toMSMEG_1726 (6 open reading frames [ORFs] of
which are annotated as transposases and 3 of which are annotated
as hypothetical proteins) (Table 2). These results strongly suggest
that mutations inmmpL3 confer resistance to BM212.
BM212-resistant isolates ofM. bovis BCG andM. tuberculo-
sisH37Rv containmutations inmmpL3.Given the identification
of mutations inmmpL3 as likely to be responsible for resistance to
BM212 in M. smegmatis, we determined the sequence of mmpL3
from the BM212-resistant M. bovis BCG and M. tuberculosis iso-
lates. Of note, all the resistant M. bovis BCG isolates had a com-
monmutation inmmpL3 that resulted in a change from leucine to
proline at position 320 (L320P) (Table 3). Some of the BCG iso-
lates also had a second nonsynonymous mutation within the
mmpL3 gene (Table 3). As shown in Fig. 2B, the majority of these
amino acid changes map within the first six transmembrane seg-
ments of the predicted topology. The mutation identified in the
mmpL3 gene of the resistant M. tuberculosis strain results in a
change from leucine to serine at position 215 (L215S) (Table 3) in
the third transmembrane segment of the predictedMmpL3 topol-
ogy (Fig. 2B).
Mutations inmmpL3donotmediate resistance toBM212 via
drug efflux. MmpL3 encodes one of the MmpL (mycobacterial
membrane protein, large) proteins, a family that has primary
structure homology to the resistance-nodulation-cell division
(RND) protein family, a group of proteins that are mainly in-
volved in drug resistance in Gram-negative bacteria (16). Since
energy-dependent bacterial efflux pumps can confer a multidrug
resistance phenotype to clinically important pathogens by extrud-
ing the drug out of the cell before it can reach its target, we felt that
it was important to exclude the possibility that resistance to
BM212 mediated by mutations in the mmpL3 gene is due to the
efflux of the compound.
We investigated whether the resistance phenotype could be
modified by broadly acting efflux pump inhibitors. We tested
three well-characterized MDR pump inhibitors; none of them
changed the susceptibility of resistant M. smegmatis isolates to
BM212 (Table 4), suggesting that mutations in the mmpL3 gene
did not cause resistance via drug efflux.
We also excluded the possibility that resistance to BM212
might be due to the overexpression of the mmpL3 gene. Quanti-
tative PCR of mmpL3 transcripts from both wild-type and
BM212-resistant M. smegmatis strains, in both the presence and
the absence of BM212, revealed no difference in mmpL3 expres-
sion (data not shown).
To further determine whether resistant M. smegmatis strains
extruded BM212 out of the cell, we formally tested the accu-
mulation and efflux of [14C]BM212 in both wild-type and
BM212-resistant (MSMEG-GR12.5)M. smegmatis strains (Fig.
3). [14C]BM212 accumulated in both strains rapidly within 5min,
at which time concentrations remained constant for the following
60 min (Fig. 3). There was no difference in the rate or quantity of
BM212 accumulation between wild-type and BM212-resistant
strains. Taken together, these data strongly suggest that themech-
anism of resistance to BM212 mediated by mmpL3 mutations is
not via drug efflux.
DISCUSSION
All antibiotics in current usage were identified through the tradi-
tional screening of small-molecule libraries for activity against
bacteria. Only subsequently was the cellular target(s) of the drug
identified, sometimes decades after the agent entered clinical use.
In some cases, such as with the first-line antitubercular agent iso-
niazid, the identification of the cellular target proved difficult and
controversial (2, 14, 19), and in others, such as with metronida-
zole, the target(s) remains elusive.
The alternative to whole-cell-based screens, target-based
screening, has failed to live up to expectations, at least for antibi-
otic development (15). Nonetheless, knowing the target of a hit
compound greatly facilitates the process of progressing fromhit to
lead compound to clinical agent.
In this study, by complementary genetic approaches, we iden-
tified mutations in the mmpL3 gene (MSMEG_0250, BCG0243c,
and Rv0206c) as being responsible for resistance to BM212, a
novel candidate antitubercular agent. We also provided evidence
that resistance to BM212 from mutations in the mmpL3 gene are
not due to an enhanced efflux of the drug, making it likely that the
mmpL3 gene product is the cellular target for BM212 activity.
One point mutation was identified in 11 out of 14 character-
izedM. smegmatismutants resistant to BM212, giving rise to sim-
ilar levels of resistance (4- to 8-fold the MIC for the wild-type
strain). These mutations are localized at different nucleotide po-
sitions, but the majority map to the first six transmembrane seg-
ments of the predicted MmpL3 topology. Two independent mu-
tants (MSMEG-BM10 and SRBM212_26) contain the same
amino acid change, V689G; the latter strain additionally contains
an 8,566-bp deletion and two other mutations. As this deleted
region contains genes coding for hypothetical proteins, trans-
TABLE 4MICs of BM212 forM. smegmatis strains grown in the
presence of efflux pump inhibitors
Compound
MIC (g/ml)a
M. smegmatis
mc2155 MSMEG_GR12.5 SRBM212_20
Reserpine 240 240 240
CCCP 30 30 NT
Verapamil 100 100 100
BM212 3 12.5 25
BM212 reserpine 3 12.5 25
BM212 CCCP 3 12.5 25
BM212 verapamil 3 12.5 25
a NT, not tested.
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posases, and pseudogenes, as annotated by SmegmaList (http:
//mycobrowser.epfl.ch/smegmalist.html), it seems unlikely that
this deletion is responsible for resistance, although further exper-
iments would be necessary to clarify the role of this large deletion
in resistance to BM212.
Two SNPs were identified in the mmpL3 gene in 5 out of 15
characterizedM. bovis isolates resistant to BM212. Onemutation,
encoding the L320P change, occurs individually in nine otherM.
bovis mutants with small differences in the BM212 MIC values.
This finding suggests that the L320P SNP is important for confer-
ring BM212 resistance and that the second SNPobserved for other
mutants (I250M, T286K, T277M, A316T, and A294T) does not
contribute to BM212 resistance. Also, in M. bovis, like M. smeg-
matis, themajority of these amino acid changesmap to the first six
transmembrane segments of the predictedMmpL3 topology. The
onlyM. tuberculosismutant resistant to BM212 presented the SNP
L215S in the third transmembrane segment.
Since no good structural model of a close homologue of
MmpL3 with significant sequence identity (40%) is available, it
is difficult to determine how themutations thatmediate resistance
could alter the association of the protein with BM212. However,
the fact that themutated amino acids all lie within predicted trans-
membrane segments is not surprising given the hydrophobicity of
the compound. However, if these amino acids do interact directly
with the compound, BM212mightwell inhibitMmpL3’s ability to
act as a transporter.
It is noteworthy that we found a higher frequency of resistance
in M. smegmatis than in both M. bovis BCG and M. tuberculosis.
One possible explanation for this finding is that mutations in M.
smegmatis mmpL3 are better tolerated, as mmpL3 appears to be
essential inM. tuberculosis (22).
MmpL3 is a putativemembrane protein belonging to the RND
protein family of multidrug resistance pumps that mediate the
transport of a diverse array of ionic or neutral compounds as well
as heavy metals and fatty acids (16). The M. tuberculosis genome
encodes 13 members of the MmpL (mycobacterial membrane
protein, large) family (6). Despite their annotation as multidrug
transporters, they do not appear to play a role in antimycobacte-
rial drug resistance (8). A recent report has ascribed a role for
mmpL3 in heme acquisition byM. tuberculosis (22), although that
role appears to be dispensable in vitro, suggesting that MmpL3
may have other functions as well.
The use of high-throughput sequencing technologies in addi-
tion to classical genetics and biochemistry provides new opportu-
nities for the rapid identification of likely targets for antibacterial
agents. Our data suggest that themmpL3 gene product is likely the
cellular target for BM212. This suggests that MmpL3 represents a
new potential druggable target for the treatment of TB. Novel
targets such as this are critical given the current epidemic of drug-
resistant TB.
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